Fenbendazole and its synthetic analog interfere with HeLa cells’ proliferation and energy metabolism via inducing oxidative stress and modulating MEK3/6-p38-MAPK pathway. (2022)

Peer-Reviewed Study · Yi Peng; Jie Pan; Fengting Ou et al. · July 1, 2022

Yi Peng et al., 2022-07-01: Peng et al. compare fenbendazole with a synthetic analogue in HeLa cervical cancer cells, finding ROS accumulation, p38-MAPK activation, impaired energy metabolism and reduced migration.

It not only activated the p38-MAPK signaling pathway, thereby inhibiting the proliferation of HeLa cells and enhancing the apoptosis of HeLa cells, but also significantly induced impaired energy metabolism and restrained their migration and invasion.

Yi Peng et al., 2022-07-01: Peng et al. compare fenbendazole with a synthetic analogue in HeLa cervical cancer cells, finding ROS accumulation, p38-MAPK activation, impaired energy metabolism and reduced migration. Study type: cell lines in vitro (HeLa and others). N: not applicable. Country: China. Dose: not stated in the abstract text captured. Funder: not stated in the record. Declared conflicts: no COI statement in the record. Comparator: the synthetic analogue 6 and normal cells. PARTLY because the metabolic finding is described as 'impaired energy metabolism' generally rather than as a named GLUT or hexokinase target, and the abstract's in vivo claim is asserted without detail. Study type: lab.